Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

被引：5
|
作者：
Prat, Aleix
Modi, Shanu
Tsurutani, Junji
Cameron, David
Harbeck, Nadia
Garrido, Charo
Karnoub, Maha
Hsu, Ching
Feng, Wenquin
Yung, Lotus
Wang, Yibin
Gambhire, Dhiraj
Ford, Shirin K.
Vitazka, Patrik
Ueno, Naoto T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-HER2-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2-18
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [22] Inter-Metastasis Heterogeneity of HER2-Low in Metastatic Breast Cancer
    Jaffer, Shabnam
    Bhardwaj, Swati
    LABORATORY INVESTIGATION, 2024, 104 (03) : S179 - S180
  • [23] HER2-low metastatic breast cancer: molecular insights and therapeutic strategies
    Esteva, Francisco J.
    Jaffer, Shabnam
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [24] Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
    Yang, Charlie
    Brezden-Masley, Christine
    Joy, Anil Abraham
    Sehdev, Sandeep
    Modi, Shanu
    Simmons, Christine
    Henning, Jan-Willem
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [25] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Zaman, K.
    Modi, S.
    Ohtan, S.
    Lee, C.
    Wang, Y.
    Saxena, K.
    Cameron, D. A.
    SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
  • [26] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [27] HER2-low Status among Patients with Li-Fraumeni Syndrome and Breast Cancer
    Auresco, Luciana
    Bonadio, Renata Colombo
    Petry, Vanessa
    Testa, Laura
    Moniz, Camila
    Dos Santos, Jennifer
    Estevez-Diz, Maria Del Pilar
    Guindalini, Rodrigo Santa Cruz
    CANCER RESEARCH, 2024, 84 (09)
  • [28] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Horisawa, Nanae
    Adachi, Yayoi
    Takatsuka, Daiki
    Nozawa, Kazuki
    Endo, Yuka
    Ozaki, Yuri
    Sugino, Kayoko
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (02) : 234 - 241
  • [29] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Nanae Horisawa
    Yayoi Adachi
    Daiki Takatsuka
    Kazuki Nozawa
    Yuka Endo
    Yuri Ozaki
    Kayoko Sugino
    Ayumi Kataoka
    Haruru Kotani
    Akiyo Yoshimura
    Masaya Hattori
    Masataka Sawaki
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 234 - 241
  • [30] Characteristics and clinical outcomes of patients with HER2-low breast cancer
    Koh, S.
    Koi, Y.
    Tajiri, W.
    Kawasaki, J.
    Akiyoshi, S.
    Nakamura, Y.
    Koga, C.
    Tokunaga, E.
    BREAST, 2023, 68 : S32 - S32
12345